Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Conditions: Carcinoma, Non-Small-Cell Lung; Metastatic Lung Cancer; Non Small Cell Lung Cancer; Lung Adenocarcinoma Metastatic; Large Cell Lung Carcinoma Metastatic Interventions: Drug: Durvalumab; Drug: Vinorelbine; Drug: Gemcitabine; Drug: nab-Paclitaxel; Drug: Carboplatin Sponsors: AIO-Studien-gGmbH; AstraZeneca; Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials